Sandbox:Sahar: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
(very low
(very low
risk)
risk)
| Cell 2 || Cell 3
|Small intraretinal tumors away from foveola and optic nerve<br>3mm or smaller in the greatest dimension, confined to the retina<br>Located further than 3 mm from the foveola and 1.5 mm from the optic disc
| Tumors ≤ 3 mm (in basal dimension or thickness)
|-
|-
!Group B
!Group B
(low risk)
(low risk)
|Cell B
|Tumors confined to the retina<br>Not in the group A<br>Tumor-associated subretinal fluid less than 3 mm from the tumor with no subretinal seeding.
|Cell C
|Tumors > 3 mm (in basal dimension or thickness) or<br>Macular location (≤ 3 mm to foveola)<br>Juxtapapillary location (≤ 1.5 mm to disc)<br>Additional subretinal fluid (≤3 mm from margin)
|-
|-
! Group C
! Group C
(moderate
(moderate
risk)
risk)
|Cell B
|Local disease with minimal subretinal or vitreous seeding with following characteristics:<br>Discrete<br>Subretinal fluid, present or past, without seeding involving up to one-fourth of the retina<br>Local fine vitreous seeding may be present close to the discrete tumor<br>Local subretinal seeding less than 3 mm (2 DD) from the tumor
|Cell C
|Tumor with:<br>Subretinal seeds ≤ 3 mm from tumor<br>Vitreous seeds ≤ 3 mm from tumor<br>Both subretinal and vitreous seeds ≤ 3 mm from retinoblastoma
|-
|-
!Group D
!Group D
(high risk)
(high risk)
|Cell B
|Diffuse tumor with significant vitreous or subretinal seeding<br>Maybe massive or diffuse<br>Subretinal fluid present or past without seeding, involving up to total retinal detachment<br>The diffuse or massive vitreous disease may include “greasy” seeds or avascular tumor masses<br>Diffuse subretinal seeding may include subretinal plaques or tumor nodules
|Cell C
|Tumor with:<br>Subretinal seeds > 3 mm from tumor<br>Vitreous seeds > 3 mm from tumor<br>Both subretinal and vitreous seeds > 3 mm from retinoblastoma
|-
|-
!Group E
!Group E
(very high
(very high
risk)
risk)
|Cell B
|Presence of any one or more of the following poor prognosis features<br>Tumor touching the lens<br>Tumor anterior to anterior vitreous face involving the ciliary body or anterior segment<br>Diffuse infiltrating retinoblastoma<br>Neovascular glaucoma<br>Opaque media from hemorrhage<br>Tumor necrosis with aseptic orbital cellulitis<br>Phthisis bulbi
|Cell C
|Extensive tumor filling >50% globe or with<br>Neovascular glaucoma<br>Opaque media from hemorrhage in the anterior chamber, vitreous or subretinal space<br>Invasion of the post-laminar optic nerve<br>choroid (>2 mm), sclera, orbit, anterior chamber
|}
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Groups}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Features}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
:Group A
| style="padding: 5px 5px; background: #F5F5F5;" |
*Small intraretinal tumors away from foveola and optic nerve
**3mm or smaller in the greatest dimension, confined to retina
**Located further than 3 mm from the foveola and 1.5 mm from the optic disc.
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
:Group B
| style="padding: 5px 5px; background: #F5F5F5;" |
*Tumors confined to the retina.
**Not in the group A
**Tumor-associated subretinal fluid less than 3 mm from the tumor with no subretinal seeding.
|-
| style="padding: 5px 5px; background: #DCDCDC;font-All remaining discrete tumors confined to the retina.weight: bold" |
:Group C
| style="padding: 5px 5px; background: #F5F5F5;" |
*Local disease with minimal subretinal or vitreous seeding with following caracteristics:
**Discrete
**Subretinal fluid, present or past, without seeding involving up to one-fourth of the retina
**Local fine vitreous seeding may be present close to the discrete tumor
**Local subretinal seeding less than 3 mm (2 DD) from the tumor
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
:Group D
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diffuse tumor with significant vitreous or subretinal seeding
**May be massive or diffuse
**Subretinal fluid present or past without seeding, involving up to total retinal detachment
**The diffuse or massive vitreous disease may include “greasy” seeds or avascular tumor masses
**Diffuse subretinal seeding may include subretinal plaques or tumor nodules
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
:Group E
| style="padding: 5px 5px; background: #F5F5F5;" |
*Presence of any one or more of the following poor prognosis features
**Tumor touching the lens
**Tumor anterior to anterior vitreous face involving the ciliary body or anterior segment
**Diffuse infiltrating retinoblastoma
**Neovascular glaucoma
**Opaque media from hemorrhage
**Tumor necrosis with aseptic orbital cellulitis
**Phthisis bulbi
|}
|}





Revision as of 15:27, 29 April 2019


Intraocular classifications of retinoblastoma and their features
International Intraocular Retinoblastoma Classification (IIRC) Intraocular Classification of Retinoblastoma (ICRB)
Group A

(very low risk)

Small intraretinal tumors away from foveola and optic nerve
3mm or smaller in the greatest dimension, confined to the retina
Located further than 3 mm from the foveola and 1.5 mm from the optic disc
Tumors ≤ 3 mm (in basal dimension or thickness)
Group B

(low risk)

Tumors confined to the retina
Not in the group A
Tumor-associated subretinal fluid less than 3 mm from the tumor with no subretinal seeding.
Tumors > 3 mm (in basal dimension or thickness) or
Macular location (≤ 3 mm to foveola)
Juxtapapillary location (≤ 1.5 mm to disc)
Additional subretinal fluid (≤3 mm from margin)
Group C

(moderate risk)

Local disease with minimal subretinal or vitreous seeding with following characteristics:
Discrete
Subretinal fluid, present or past, without seeding involving up to one-fourth of the retina
Local fine vitreous seeding may be present close to the discrete tumor
Local subretinal seeding less than 3 mm (2 DD) from the tumor
Tumor with:
Subretinal seeds ≤ 3 mm from tumor
Vitreous seeds ≤ 3 mm from tumor
Both subretinal and vitreous seeds ≤ 3 mm from retinoblastoma
Group D

(high risk)

Diffuse tumor with significant vitreous or subretinal seeding
Maybe massive or diffuse
Subretinal fluid present or past without seeding, involving up to total retinal detachment
The diffuse or massive vitreous disease may include “greasy” seeds or avascular tumor masses
Diffuse subretinal seeding may include subretinal plaques or tumor nodules
Tumor with:
Subretinal seeds > 3 mm from tumor
Vitreous seeds > 3 mm from tumor
Both subretinal and vitreous seeds > 3 mm from retinoblastoma
Group E

(very high risk)

Presence of any one or more of the following poor prognosis features
Tumor touching the lens
Tumor anterior to anterior vitreous face involving the ciliary body or anterior segment
Diffuse infiltrating retinoblastoma
Neovascular glaucoma
Opaque media from hemorrhage
Tumor necrosis with aseptic orbital cellulitis
Phthisis bulbi
Extensive tumor filling >50% globe or with
Neovascular glaucoma
Opaque media from hemorrhage in the anterior chamber, vitreous or subretinal space
Invasion of the post-laminar optic nerve
choroid (>2 mm), sclera, orbit, anterior chamber
Groups Features
Group A
  • Small intraretinal tumors away from foveola and optic nerve
    • 3mm or smaller in the greatest dimension, confined to retina
    • Located further than 3 mm from the foveola and 1.5 mm from the optic disc.
Group B
  • Tumors confined to the retina.
    • Not in the group A
    • Tumor-associated subretinal fluid less than 3 mm from the tumor with no subretinal seeding.
Group C
  • Local disease with minimal subretinal or vitreous seeding with following caracteristics:
    • Discrete
    • Subretinal fluid, present or past, without seeding involving up to one-fourth of the retina
    • Local fine vitreous seeding may be present close to the discrete tumor
    • Local subretinal seeding less than 3 mm (2 DD) from the tumor
Group D
  • Diffuse tumor with significant vitreous or subretinal seeding
    • May be massive or diffuse
    • Subretinal fluid present or past without seeding, involving up to total retinal detachment
    • The diffuse or massive vitreous disease may include “greasy” seeds or avascular tumor masses
    • Diffuse subretinal seeding may include subretinal plaques or tumor nodules
Group E
  • Presence of any one or more of the following poor prognosis features
    • Tumor touching the lens
    • Tumor anterior to anterior vitreous face involving the ciliary body or anterior segment
    • Diffuse infiltrating retinoblastoma
    • Neovascular glaucoma
    • Opaque media from hemorrhage
    • Tumor necrosis with aseptic orbital cellulitis
    • Phthisis bulbi


  • Chief cells Arranged in distinctive pattern called cell balls (zellballen)
  • Separated by fibrovascular stroma and surrounded by sustentacular cells
  • The cytoplasm is pale and diffuse with occasional presence of the eosinophilic granules.[2]
  • The nuclei are round to spindle shape.
Diagnostic algorithm for Infantile onset glyogen storage disease type II
Features on Gross Pathology Image
Characteristic findings of carotid body tumor, include:[3]
    • Well-circumscribed with psudocapsule
    • The size of the tumor varies greatly and it may be as large as 10 cm
    • The cutting surface is solid with a smooth, rubbery texture||
Contributed by Paweł Kuźniar in wikimedia.commons
 
 
 
 
 
 
 
 
 
 
 
Patient with carotid body tumor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History, Physical examination, and evaluation of cnotralateral side
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with age < 50 years
Patients with multiple paraganglioma
Patients with a positive family history
 
 
 
The rest of the patients
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDHD genetic testing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of SDHD mutation
 
 
 
 
Absence of SDHD mutation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDHC and SDHB genetic testing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of SDHC/B mutation
 
 
 
Absence of SDHC/B mutation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the relatives should be evaluated for the presence of paragnaglioma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
whole-body 18F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of other paraganglioma
 
 
 
Absence of other paraganglioma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24-hour urine catecholamines and MRI for biochemical screening
 
 
 
surveillance screening every 5 years
  1. Patetsios, Peter; Gable, Dennis R.; Garrett, Wilson V.; Lamont, Jeffrey P.; Kuhn, Joseph A.; Shutze, William P.; Kourlis, Harry; Grimsley, Bradley; Pearl, Gregory J.; Smith, Bertram L.; Talkington, C.M.; Thompson, Jesse E. (2002). "Management of Carotid Body Paragangliomas and Review of a 30-year Experience". Annals of Vascular Surgery. 16 (3): 331–338. doi:10.1007/s10016-001-0106-8. ISSN 0890-5096.
  2. Bibbo, Marluce (2008). Comprehensive cytopathology. Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4160-4208-2.
  3. 3.0 3.1 Wieneke, Jacqueline A.; Smith, Alice (2009). "Paraganglioma: Carotid Body Tumor". Head and Neck Pathology. 3 (4): 303–306. doi:10.1007/s12105-009-0130-5. ISSN 1936-055X.